Makes specialty chemicals across four operating segments — Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Pharma & Specialty Chemical intermediates (PASC) and Electrolyte Salts. In Q1 FY27 the four segments generated segment revenue of ₹428M (PTC), ₹578M (SDA), ₹584M (PASC) and ₹63M (Electrolyte Salts); PTC is positioned as a process-enabling chemistry technology and SDA serves emissions-control applications where Euro 7 implementation is translating into revenue. PASC covers pharma intermediates, with the first molecule entering commercial production in Q1 FY27 and three new molecules expected to add ₹70-80 crore in FY27. The Dahej manufacturing site is essentially saturated and a Dahej-III greenfield unit has been approved with groundbreaking on 20 July 2026, targeting about ₹300 crore peak revenue. The largest input cost is raw materials at 51.9% of revenue, with amines among those whose prices have risen 30-40% on geopolitical factors; most increases are being passed to customers. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. PTC (Phase Transfer Catalysts), SDA (Structure Directing Agents), PASC (Pharma & Specialty Chemical Intermediates), Electrolyte Salts. Multi-vertical specialty chemicals manufacturer, asset-heavy with capacity expansions underway
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 434 | 424 | 394 | 383 | 506 |
| EBITDA (ex other income) | 108 | 57 | 68 | 34 | 93 |
| margin % | 25.0 | 13.5 | 17.3 | 8.9 | 18.4 |
| Owners' profit | 96 | 45 | 30 | 6 | 42 |
| EPS, as reported (₹) | 44.59 | 20.52 | 13.26 | 2.44 | 17.98 |
| ROE % · ROCE % | 20.3 · 22.4 | 8.8 · 10.2 | 4.1 · 6.8 | 0.8 · 1.2 | 5.4 · 7.6 |
| Debt / equity (x) | 0.25 | 0.33 | 0.02 | 0.05 | 0.15 |
| Cash from operations | 20 | 28 | 98 | 25 | 31 |
| Capex | (89) | (203) | (129) | (76) | (114) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 86 | 108 | 117 | 124 | 131 | 134 | 167 |
| Profit before tax | (1) | (0) | 2 | 9 | 14 | 18 | 17 | 21 |
| Net profit | (1) | 0 | 1 | 7 | 10 | 15 | 10 | 16 |
| EPS (₹) | (0.29) | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 | 4.41 | 6.83 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Tatva Chintan to hold investor meeting with HSBC on Sep 15 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · CRISIL upgrades Tatva Chintan credit rating to A- | credit debt | high | — | — |
| 28 Aug 2026 · Tatva Chintan publishes newspaper notice for 30th AGM | compliance | minimal | — | — |
| 27 Aug 2026 · Record date fixed at 11 Sep 2026 for final dividend FY25-26 | corporate actions | high | — | — |
| 27 Aug 2026 · Tatva Chintan submits BRSR for FY 2025-26 | compliance | minimal | — | — |
| 27 Aug 2026 · 30th AGM on Sep 25: dividend Rs 2 per share, director re-appointments, higher borrowing limit | board shareholder meetings | low | — | — |
| 19 Aug 2026 · AVP Research and Development resigns from Tatva Chintan | management changes | medium | — | — |
| 19 Aug 2026 · AVP R&D Ajay Rawat resigns, effective 13 Nov 2026 | management changes | medium | — | — |
| 18 Aug 2026 · AGM notice published in newspapers, 30th AGM on 25 Sept 2026 | compliance | minimal | — | — |
| 11 Aug 2026 · Tatva Chintan announces final dividend Rs 2/share for FY26; TDS intimation | corporate actions | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| AETHER INDUSTRIES LIMITED | 22,229 | 94.3 | 9.05 | 60.4 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 72.9 | 23.4 | 88 of 103 | 15% |
| P/B | 4.8 | 2.9 | 74 of 99 | 26% |
| ROCE | 7.2 | 10.3 | 65 of 108 | 40% |
| ROE | 5.4 | 8.1 | 67 of 101 | 34% |
| Debt / Equity | 0.1 | 0.2 | 48 of 101 | 53% |
| EBITDA margin | 20.2 | 15.5 | 37 of 99 | 63% |
| Revenue growth | 43.0 | 24.4 | 20 of 94 | 80% |
| Profit growth | 140.3 | 55.1 | 23 of 92 | 76% |
| Market cap | 3748 | 732 | 29 of 107 | 74% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
